IL2 and neoplasm: Thus, we are exploring the utility of a new tool for manipulating the Vδ2 T cell capacity for tumor suppression and believe it can be combined with PAg or bisphosphonate stimulation, IL-2 treatment and ex vivo expanded autologous or allogeneic effector cells in a continuing effort to develop potent treatment strategies.